AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meetin
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq rise in choppy trading as tech steadies, Micron results in focus
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
AbbVie (ABBV) Announces Additional Data on IMBRUVICA Phase 3 in CLL/SLL
June 6, 2016 9:03 AM EDTAbbVie (NYSE: ABBV) announced longer-term follow-up results from Phase 3 studies of IMBRUVICA (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). Findings include an analysis of outcomes from the RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115) trials, which showed IMBRUVICA was associated with favorable progression-free survival (PFS) and overall survival (OS) regardless of line of therapy (previously treated or treatment-naïve; abstract 7520). Other data include first-ever presentation of longer-term follow-up data from the HELIOS (CLL3001) trial showing... More
Cowen Cuts Abbvie (ABBV) to Market Perform; Analyst Calls Rova-T Data at ASCO 'Underwhelming'
June 6, 2016 7:36 AM EDT(Updated - June 6, 2016 9:21 AM EDT)
Cowen downgraded Abbvie (NYSE: ABBV) from Outperform to Market Perform with a price target of $70 (prior $77). Analyst Steve Scala called Rova-T data at ASCO "underwhelming." Overall, he sees opportunities as balanced.
"Last Fridays analyst meeting was solid, but provided limited news to bolster visibility on the L-T outlook. Rova-T data at ASCO was underwhelming and does not enhance confidence in capital deployment post the $5.8B Stemcentrx acquisition. ABBV stock has been a good performer, despite the recent Humira IPR, offering opportunity to lock in profits. We believe... More
AbbVie (ABBV) Issues Positive Update on Rova-T as r/r SCLC Treatment
June 6, 2016 6:26 AM EDTAbbVie (NYSE: ABBV) announced that treatment with rovalpituzumab tesirine (Rova-T), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC), demonstrated a confirmed overall response rate (ORR) of 39 percent and clinical benefit rate (stable disease or better) of 89 percent in patients with recurrent or refractory small cell lung cancer (SCLC), identified with high expression of DLL3. Rova-T demonstrated a one-year overall survival (OS) rate of 32 percent in the recurrent/refractory second- and third-line patient population. These new data were presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in... More
